18 October 2023 - NICE has published final evidence based recommendations on the use of daridorexant hydrochloride (Quviviq) for the treatment of patients with long-term insomnia.

Daridorexant hydrochloride is recommended for the treatment of adults with insomnia with symptoms lasting for three nights or more per week for at least three months, and whose daytime functioning is considerably affected, only if:

• Cognitive behavioural therapy for insomnia has been tried but not worked, or
• Cognitive behavioural therapy is not available or is unsuitable

Read NICE technology appraisal guidance